参考文献/References:
[1] Davies L,Welch HG,Increasing incidence of thyroid cancer in the United States,1973-2002,JAMA,2006,295(18):2164-2167.
[2] Karam M,Gianoukakis A,Feustel PJ,et al.Influence of diagnostic and therapeutic doses on thyroid remnant ablation rates.Nucl Med Commun,2003,24(5):489-495.
[3] Bal CS,Kumar A,Pant GS.Radioiodine dose for remnant ablation in differentiated thyroid carcinoma:a randomized clinical trial in 509 patients.J Clin Endocrinol Metab,2004,89(4):1666-1673.
[4] Sawka AM,Thephamongkhol K,Brouwers M,et al.Clinical review 170:A systematic review and meta analysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer.J Clin Endocrinol Metab,2004,89(8):3668-3676.
[5] 朱瑞森,余永利,陆汉魁,等.分化型甲状腺癌术后131I治疗的必要性.上海交通大学学报(医学版),2006,26(9):1042-1043,1055.
[6] 余永利,罗全勇,陈立波,等.分化型甲状腺癌术后131I治疗生存率分析.中华核医学杂志,2006,26(5):261-263.
[7] Hershman JM,Edwards CL.Serum thyrotropin (TSH) levels after thyroid ablation compared with TSH levels after exogenous bovine TSH:implications for 131-I treatment of thyroid carcinoma.J Clin Endocrinol Metab,1972,34(5):814-818.
[8] Hackshaw A,Harmer C,Mallick U,et al.131I activity for remnant ablation in patients with differentiated thyroid cancer:A systematic review.J Clin Endocrinol Metab,2007,92(1):28-38.
[9] 朱旭生,邹德环,佘立群,等.大剂量131I对分化型甲状腺癌患者术后剩余甲状腺组织的去除治疗.中国肿瘤,2007,16(4):279-281.
[10] 傅宏亮,王辉,吴靖川,等.影响分化型甲状腺癌术后131I清甲治疗疗效的因素分析.中华核医学杂志,2009(3):149-152.
[11] Dorn R,Kopp J,Vogt H,et al.Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer:largest safe dose using a risk-adapted approach.J Nucl Med,2003,44(3):451-456.
[12] Samuel AM,Rajashekharrao B.Radioiodine therapy for well-differentiated thyroid cancer:a quantitative dosimetric evaluation for rem nant thyroid ablation after surgery.J Nucl Med,1994,35(12):1944-1950.
[13] Coover LR,Silberstein EB,Kuhn PJ,et al.Therapeutic 131I in outpatients:a Simplified method conforming to the Code of Federal Regulations title 10,part 35.75.J Nucl Med,2000,41(11):1868-1875.
[14] Cholewinski SP,Yoo KS,Klieger PS,et al.Absence of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I.J Nucl Med,2000,41(7):1198-1202.
[15] 赵劼,孙辉,温强,等.分化型甲状腺癌术后131I清除剩余甲状腺及治疗甲癌转移灶的临床作用.吉林医学,2006,27(2):117-118.
[16] Liel Y.Preparation for radioactive iodine administration in differentiated thyroid cancer patients.Clin Endocrinol (Oxf),2002,57(4):523-527.
[17] Grigsby PW,Siegel BA,Bekker S,et al.Preparation of patients with thyroid cancer for 131I scintigraphy or therapy by 1-3 weeks of thyroxine discontinuation.J Nucl Med,2004,45(4):567-570.
[18] Klain M,Ricard M,Leboulleux S,et al.Radioiodine therapy for papillary and follicular thyroid carcinoma.Eur J Nucl Med Mol Imaging,2002,29(Suppl 2):S479-S485.
[19] Pacini F,Ladenson PW,Schlumberger M,et al.Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma:results of an international,randomized,controlled study.J Clin Endocrinol Metab,2006,91(3):926-932.
[20] Barbaro D,Boni G,Meucci G,et al.Recombinant human thyroidstimulating hormone is effective for radioiodine ablation of postsurgical thyroid remnants.Nucl Med,2006,27(8):627-632.
[21] Sawka AM,Orlov S,Gelberg J,et al.Prognostic value of postsurgical stimulated thyroglobulin levels after initial radioactive iodine therapy in well-differentiated thyroid carcinoma.Head Neck,2008,30(6):693-700.
[22] 高再荣,常伟,崔坤炜,等.甲状腺乳头状癌术后刺激状态Tg预测131I清甲治疗后Tg水平的价值.中华核医学杂志,2009(3):156-159.
[23] Verkooijen RB,Stokkel MP,Smit JW,et al.Radioiodine-131 in differentiated thyroid cancer:a retrospective analysis of an uptakerelated ablation strategy.Eur J Nucl Med Mol Imaging,2004,31(4):499-506.
[24] Kumar A,Bat CS.Differentiated thyroid cancer.Indian J Pediatr,2003,70(9):707-713.
[25] 王全林,刘玲.分化型甲癌术后131I首次去除残留组织效果的影响因素.华西医学,2001,16(1):55-56.
[26] 季鸿,朱瑞森,余永利,等.甲状腺癌术后131I首次清除剩余甲状腺疗效分析.中华核医学杂志,2001,21(2):91-92.
[27] Simon D,Koehrle J,Reiners C,et al.Redifferentiation therapy with retinoids:therapeutic option for advanced follicular and papillary thyroid carcinoma.World J Surg,1998,22(6):569-574.
[28] Luster M,Lippi F,Jarzab B,et al.rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma:a comprehensive review.Endocr Relat Cancer,2005,12(1):49-64.
[29] Cho JY.A transporter gene (sodium iodine symporter) for dual purposes in gene therapy:imaging and therapy.Curr Gene Ther,2002,2(4):393-402.
相似文献/References:
[1]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[2]李盼丽,宋少莉.碘难治性分化型甲状腺癌靶向药物治疗进展[J].国际放射医学核医学杂志,2016,40(3):202.[doi:10.3760/cma.j.issn.1673-4114.2016.03.009]
Li Panli,Song Shaoli.Radioactive iodine refractory differentiated thyroid cancer targeted therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):202.[doi:10.3760/cma.j.issn.1673-4114.2016.03.009]
[3]邓艳,张伟.125I-碘酞酸盐临床应用进展[J].国际放射医学核医学杂志,2016,40(3):225.[doi:10.3760/cma.j.issn.1673-4114.2016.03.012]
Deng Yan,Zhang Wei.125I-iothalamate clinical applications[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):225.[doi:10.3760/cma.j.issn.1673-4114.2016.03.012]
[4]田琦,蒋宁一,郑丽.265例精细个体化131I治疗Graves甲亢的疗效观察[J].国际放射医学核医学杂志,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
Tian Qi,Jiang Ningyi,Zheng Li.Therapeutic effect of fine individual 131I treatment on Graves disease hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
[5]刘娇,程兵,常伟,等.非高危分化型甲状腺癌低剂量和高剂量131I清甲疗效的分析[J].国际放射医学核医学杂志,2016,40(6):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
Liu Jiao,Cheng Bing,Chang Wei,et al.Ablation efficacy in non-high-risk differentiated thyroid carcinoma patients with low-dose and high-dose 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
[6]徐蓉生,梅艳,赵力威,等.B超引导下术中125I粒子植入治疗晚期胰腺癌的疗效评价[J].国际放射医学核医学杂志,2016,40(6):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
Xu Rongsheng,Mei Yan,Zhao Liwei,et al.Evaluation of 125I particle implantation in the treatment of patients with advanced pancreatic neoplasms using B ultrasound-guided surgery[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
[7]陈立,陈跃.分化型甲状腺癌骨转移诊断及疗效评价的核素显像研究进展[J].国际放射医学核医学杂志,2016,40(6):452.[doi:10.3760/cma.j.issn.1673-4114.2016.06.010]
Chen Li,Chen Yue.Diagnosis and evaluation of curative effect progress of radionuclide imaging methods in differentiated thyroid cancer of bone metastases[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):452.[doi:10.3760/cma.j.issn.1673-4114.2016.06.010]
[8]王越,晋建华,李思进,等.甲状腺24h摄碘率与131I治疗Graves甲亢疗效相关性研究[J].国际放射医学核医学杂志,2015,39(6):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
Wang Yue,Jin Jianhua,Li Sijin,et al.Correlation between thyroid 24 h of radioactive iodine uptake and clinical efficacy of 131I therapy for Graves’ hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
[9]郭坤,高蕊,于燕,等.表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系[J].国际放射医学核医学杂志,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
Guo Kun,Gao Rui,Yu Yan,et al.The relationship between epidermal growth factor receptor mRNA expression and the efficacv of 131I treatment in hyperthyroidism patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
[10]赵腾,梁军,林岩松.131I治疗前刺激性Tg在分化型甲状腺癌风险评估及治疗决策中的意义[J].国际放射医学核医学杂志,2015,39(1):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
Zhao Teng,Liang Jun,Lin Yansong.The role of preablative stimulated thyroglobulin in guiding risk estimation and therapeutic decisions of differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
[11]杨珂,唐波,于夕荣,等.甲状腺癌131i治疗病房的辐射屏蔽计算与评价[J].国际放射医学核医学杂志,2015,39(5):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
yang ke,tang bo,yu xirong,et al.shielding calculation and assessment in 131i therapy for thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
[12]寇莹,刘建中,郝新忠,等.甲状腺癌131I治疗后全身扫描盆腔浓聚131I的临床分析[J].国际放射医学核医学杂志,2014,38(1):15.[doi:10.3760/cma.j.issn 1673-4114.2014.01.004]
Kou Ying,Liu Jianzhong,Hao Xinzhong,et al.Analysis of pelvic 131I uptake after 131I whole body scan in patients with thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(1):15.[doi:10.3760/cma.j.issn 1673-4114.2014.01.004]
[13]李敬彦,蒋宁一.分化型甲状腺癌术后131I清甲治疗方法的相关问题[J].国际放射医学核医学杂志,2014,38(1):42.[doi:10.3760/cma.j.issn 1673-4114.2014.01.009]
Li Jingyan,Jiang Ningyi.Issues related to radioactive iodine ablation in patients with differentiated thyroid carcinoma under-going thyroid surgery[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(1):42.[doi:10.3760/cma.j.issn 1673-4114.2014.01.009]
[14]成钊汀,谭建.分化型甲状腺癌术后患者131I治疗的辐射剂量与防护[J].国际放射医学核医学杂志,2014,38(2):110.[doi:10.3760/cma.j.issn.1673-4114.2014.02.010]
Cheng Zhaoting,Tan Jian.Radiation dose and protection of differentiated thyroid carcinoma postoperative patients with 131I treatment[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(1):110.[doi:10.3760/cma.j.issn.1673-4114.2014.02.010]
[15]李莉,晋建华,陆克义,等.131I去除分化型甲状腺癌术后残留甲状腺组织疗效的meta分析[J].国际放射医学核医学杂志,2014,38(3):152.[doi:10.3760/cma.j.issn.1673-4114.2014.03.003]
Li Li,Jin Jianhua,Lu Keyi,et al.A meta-analysis of efficacy of iodine-131 for post-thyroidectomy ablation of remnants in patients with differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(1):152.[doi:10.3760/cma.j.issn.1673-4114.2014.03.003]
[16]李永军,徐兆强,柳卫,等.分化型甲状腺癌术后131I治疗患者胸腺生理性摄取131I的临床研究[J].国际放射医学核医学杂志,2014,38(4):227.[doi:10.3760/cma.j.issn.1673-4114.2014.04.005]
Li Yongjun,Xu Zhaoqiang,Liu Wei,et al.Clinical research on physiological thymic uptake of 131I in post-operative patients with differentiated thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(1):227.[doi:10.3760/cma.j.issn.1673-4114.2014.04.005]
[17]张璐,詹维伟,张一帆.颈部超声在分化型甲状腺癌131I治疗中的应用进展[J].国际放射医学核医学杂志,2014,38(4):271.[doi:10.3760/cma.j.issn.1673-4114.2014.04.015]
Zhang Lu,Zhan Weiwei,Zhang Yifan.Application of neck ultrasonography in 131I radiotherapy of differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(1):271.[doi:10.3760/cma.j.issn.1673-4114.2014.04.015]
[18]汤敏敏,刘建中,武志芳,等.分化型甲状腺癌患者131I治疗后体内残留放射性活度的评估[J].国际放射医学核医学杂志,2014,38(6):363.[doi:10.3760/cma.j.issn.1673-4114.2014.06.004]
Tang Min-min,Liu Jian-zhong,Wu Zhi-fang,et al.Estimation of residual activities in patients with differentiated thyroid cancer after administration of 131I for therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(1):363.[doi:10.3760/cma.j.issn.1673-4114.2014.06.004]
[19]侯莎莎,沈婕,秦岚.131I全身显像及血清甲状腺球蛋白测定在分化型甲状腺癌治疗随访中的作用[J].国际放射医学核医学杂志,2013,37(5):269.[doi:10.3760/cma.j.issn.1673-4114.2013.05.004]
HOU Sha-sha,SHEN Jie,QIN Lan.Significance of 131I whole body scan combined with serum thyroglobulin in the follow-up of differentiated hyroid cancer after thyroid ablation[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(1):269.[doi:10.3760/cma.j.issn.1673-4114.2013.05.004]
[20]易艳玲,石洪成,顾宇参,等.分化型甲状腺癌患者日尿排泄131I活度分数估算[J].国际放射医学核医学杂志,2010,34(4):226.[doi:10.3760/cma.j.issn.1673-4114.2010.04.010]
YI Yah-ling,SHI Hong-cheng,GU Yu-shen,et al.Estimation the daily urinary excretion 131I radioactivity of patients with differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(1):226.[doi:10.3760/cma.j.issn.1673-4114.2010.04.010]